Key result
BP reduction with propranolol, bendroflumethiazide, or verapamil shows no consistent link to calcium metabolism.
Why the study?
Disturbances of calcium metabolism accompany essential hypertension, but it is unknown whether these alterations are primary or secondary to elevated blood pressure.
Do different antihypertensive agents (propranolol, bendroflumethiazide, verapamil) alter calcium metabolic indices in patients with essential hypertension?
Cohort (n=35)
Do different antihypertensive agents (propranolol, bendroflumethiazide, verapamil) alter calcium metabolic indices in patients with essential hypertension?
Changes in calcium metabolism observed in essential hypertension appear to be specific to the antihypertensive agent used rather than directly related to the degree of blood pressure reduction.
Disturbances of calcium metabolism appear primary in essential hypertension; leaves open causal role and requires larger prospective trials before clinical consideration.
Disturbances of calcium metabolism, mimicking mild, compensated secondary hyperparathyroidism, accompany essential hypertension, but it is not known whether these alterations are primary or only secondary to the elevated blood pressure. 2. Indices of systemic calcium metabolism were followed prospectively during 6 months' treatment with either propranolol, bendroflumethiazide or verapamil in 35 patients with essential hypertension. Multivariate statistical methods were employed to study the effects of blood pressure reduction upon the metabolic indices with adjustment for the effects of the different antihypertensive agents. 3. Propranolol treatment increased the plasma ionized calcium and serum phosphate concentrations, and reduced the serum levels of parathyroid hormone, free fatty acids and glycerol. Neither the total nor the total albumin-modified serum calcium concentration was significantly affected. Thus, presumably the decrease in free fatty acids reduced the calcium complex and the calcium binding to albumin, and consequently increased the plasma ionized calcium, thereby suppressing the secretion of parathyroid hormone. 4. Bendroflumethiazide caused a reduction of the fasting renal calcium excretion to half the pretreatment level, but produced no other significant changes in the various indices of calcium metabolism. 5. During verapamil treatment, the fasting renal excretion of calcium and magnesium increased, whereas the free fatty acids and glycerol concentrations in serum were reduced. These two changes presumably balanced each other, as the plasma ionized calcium and serum parathyroid hormone concentrations were not significantly altered. 6. There were no consistent relationships between the decrease in blood pressure and the changes in the metabolic indices, either in the total sample or within any subgroup.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Hvarfner et al. (1988) conducted a cohort in essential hypertension (n=35). Propranolol, bendroflumethiazide, or verapamil was evaluated on Effects of blood pressure reduction upon calcium metabolic indices. Treatment with propranolol, bendroflumethiazide, or verapamil for 6 months showed no consistent relationships between blood pressure reduction and changes in calcium metabolic indices.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: